Amarin Corp Plc (AMRN)

[jfmcrr]

Not overly surprised here. We've dealt with skepticism for over five years, and get that we are ahead of the curve, thanks to some pretty amazing posters, in terms of understanding of the method of action and implications of Vascepa as a treatment for systemic inflammation, including CVD issues.
In my opinion, shared I think by many others here--smarter than me; I've benefited from there sharing--the medical community and investment community will have a greater grasp of what V can do after this weekend's presentations at the AHA conference in Chicago. Amarin gave a glimpse on Sept 24th, bu only explicitly provided topline data. Skepticism runs deep regarding V working, though, so many are hedging until they see the Secondary Endpoints (SEs) reported out, which happens 11/10 around 2:30.

There is also the possibility that there are portfolio managers who still see the one number release about a successful "fish oil" as still risky (to their career) but are prepped to explain how this story has legs and they need to be in it now when Saturday goes well. Rising tide and all that.